The aims of the Australasian Gene and Cell Therapy Society (AGCTS)
To facilitate the growth and development of the field of gene and cell therapy in Australasia
To represent the goals of the Australasian gene and cell therapy community before government and the public
To disseminate information regarding the safe and ethical use of gene and cell therapy methodologies
To act as a resource of gene and cell therapy protocols, reagents and scientific exchanges
Dear AGCTS Membership & Associates,
At our 2014 Annual General Meeting, we unanimously voted for a name change to the Australasian Gene and Cell Therapy Society (AGCTS) to reflect the broader interests of our society members in cell biology, particularly the use of stem cells in delivering gene medicines. The name change of our Society was finalised in 2015, announced to our membership and associates via email. You are now looking at our new website www.agcts.org.au.
At that meeting, the Executive Committee heard the membership loud and clear. Stronger links must be forged with cell therapy and stem cell research community. To achieve this goal we have partnered with the Australasian Society for Stem Cell Research (ASSCR) to deliver what is shaping up to be an inspiring and exciting Scientific Program with an incredible line-up of international research leaders and clinicians 24th – 26th May 2017, UTS Aeriel Function Centre, Sydney.
I would like to acknowledge the already enormous contribution of the Joint 10th AGCTS and ASSCR Conference Organising Committee who have volunteered their time to make this meeting a success. I’d like to individually thank our AGCTS VP Jim Vadolas, Treasurer Ann Simpson, Secretary Samantha Ginn, Exec Members Paul Gregorevic, Sharon Cunningham, Marguerite Evans-Galea, Ex-officio member Steve Wilton and ASSCR President Melissa Little, past-President Michael O’Connor, VP Ed Stanley, Treasurer Robyn Meech, Secretary Michael Morris, Exec Members Michael Doran, Margret Schuller, Helen Abud, Trish Barker.
I am very proud to be leading a dedicated society which has continued to provide advocacy for Australian research in the development of molecular medicines, cell and gene therapies. Our membership works tirelessly to reduce the impact of some of Australia’s largest health problems and improve the well being of those diagnosed with acquired or genetic disease. Focus areas of our membership are broad and include cancer, viral infection (HIV, Hepatitis B & C), autoimmunity, immunodeficiency, diabetes, metabolic disease, blood, eye, ear and muscle disorders.
Although there have been considerable funding challenges of late, momentum is clearly building thanks to the enormous commitment and perseverance and of our researchers, clinicians, industry leaders and regulators. The AGCTS Executive Committee and I feel privileged to represent you and our sector in this very exciting journey and witness first-hand the translation of our field into the clinic which will be featured at our next meeting.
Rosetta Martiniello-Wilks PhD
President, Australasian Gene and Cell Therapy Society www.agcts.org.au